Pharmacology
Do GLP-1 drugs help as add-ons in type 1 diabetes?
Open access · cc by · source: Europe PMC
Across 11 RCTs (2,856 adults), GLP-1 RA add-on therapy modestly lowered HbA1c (−0.21%), weight (−4.04 kg), and insulin doses without more severe hypo/DKA, but GI adverse events rose (OR 2.96).
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
GLP-1RAs can be studied as add-on therapy to insulin in type 1 diabetes.
A systematic/clinical synthesis evaluates glucagon-like peptide-1 receptor agonists added to insulin for type 1 diabetes—glucose and weight outcomes under insulin co-therapy.
Evidence for the claim as stated.
Different GLP-1RAs have been linked to acute pancreatitis in pharmacovigilance-style case series.
A case-series analysis associates specific GLP-1 receptor agonists with acute pancreatitis reports—useful for safety signal literacy, not incidence rates.
Scope note — efficacy add-on ≠ spontaneous pancreatitis reports
Limits the claim's scope: a different population, assay, or outcome.
In US EHR data, starting tirzepatide associated with fewer deaths and CV/kidney events than starting a GLP-1 RA.
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
Scope note — T1D insulin add-on synthesis ≠ T2D dual-agonist vs GLP-1 RA comparative cohort
Limits the claim's scope: a different population, assay, or outcome.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
Evidence for the claim as stated.
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
GLP-1RAs studied for metabolic benefit on insulin vs Case series flag pancreatitis with some agents
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study, not a biliary FAERS ROR, and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
History
When this study was placed
Dated entries from the concept change log — when this paper was added or removed as support, challenge, or qualifier on a claim.
Placed as a scope qualifier on GLP-1 receptor agonists
Among 140,308 matched US adults with type 2 diabetes, tirzepatide vs a GLP-1 receptor agonist associated with lower all-cause mortality (AHR 0.58), MACEs (AHR 0.80), kidney events (AHR 0.52), AKI (AHR 0.78), and MAKEs (AHR 0.54) over a median 10.5 months, with larger HbA1c and weight drops.
Placed as supporting evidence on GLP-1 receptor agonists
A T2D EHR comparison of tirzepatide versus GLP-1 RAs is not a pancreatitis incidence study and is not a T1D add-on trial. Class talk still needs the indication, comparator, and design named.
Study at a glance
- Design
- Meta-analysis / systematic review — Random-effects meta-analysis of RCTs of GLP-1 RAs as add-on to insulin in adult T1D
- N
- N=2856 · 11 trials; 2,856 participants from 1,379 screened records
- Population
- Adults with type 1 diabetes on insulin
- Outcome
- Change in HbA1c plus weight, BP, insulin doses, and selected adverse events
Structured fields used in claim comparison tables when every cited study has a complete layer.
Inspect source passages
Do GLP-1 drugs help as add-ons in type 1 diabetes?
These passages occur verbatim in the stored paper text. They support the points listed below; they do not verify every statement in the explanation.
11 trials with 2,856 participants included.
Among 1,379 candidate studies, 11 trials comprising 2,856 participants satisfied the inclusion criteria.
HbA1c reduced by −0.21%; weight by −4.04 kg.
Overall, GLP-1 RA adjunctive therapy reduced HbA1c by −0.21% (95% CI, −0.33 to −0.10), weight by −4.04 kg (−4.8 to −3.27), systolic pressure by −2.57 mmHg (−4.11 to −1.03), and diastolic blood pressure by −1.02 mmHg (−1.99 to −0.06).
Key findings
HbA1c −0.21%; weight −4.04 kg; SBP −2.57 and DBP −1.02 mmHg; prandial/basal/total insulin doses decreased. No increase in severe hypoglycemia, DKA, or severe adverse events, but gastrointestinal AEs increased (OR 2.96).
Methodology
Searched Medline/Embase/CENTRAL to May 2021 and meta-analyzed randomized trials of GLP-1 receptor agonists added to insulin in adults with type 1 diabetes (primary endpoint: HbA1c change).
Limitations
Pooled RCTs cannot settle long-term cardiorenal outcomes or individual agent ranking; GI intolerance may limit real-world uptake.
Related papers in this topic
Same topic cluster — not a recommendation engine.